المؤلفون: Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park

المصدر: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-11 (2024)

مصطلحات موضوعية: Enavogliflozin, Glycemic control, Non-insulin dependent diabetes mellitus, SGLT-2 inhibitor, Urine glucose excretion rate, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1475-2840Test

الوصول الحر: https://doaj.org/article/60b24246100e499594c4cfe5d70b4d87Test

المؤلفون: Juan Esteban Gómez-Mesa, Clara Saldarriaga, Alex Arnulfo Rivera-Toquica, Silfredo Arrieta-González, Alfonso Muñoz-Velásquez, Eduardo José Echeverry-Navarrete, Julián Rodrigo Lugo-Peña, Juan Alberto Cerón, Oscar Sveins Rincón-Peña, Luis Eduardo Silva-Diazgranados, Hugo Ernesto Osorio-Carmona, Alejandro Posada-Bastidas, Juan Camilo García, Alejandro David Ochoa-Morón, Luis Eduardo Echeverría

المصدر: International Journal of Cardiology: Heart & Vasculature, Vol 53, Iss , Pp 101448- (2024)

مصطلحات موضوعية: Heart failure, SGLT-2 inhibitor, Ejection fraction, Empagliflozin, Colombia, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2352906724001143Test; https://doaj.org/toc/2352-9067Test

الوصول الحر: https://doaj.org/article/ab6e7264f06a4dbcbd92f67ee0640f68Test

المؤلفون: Fatih Ozturk, Hasim Tuner, Adem Atici, Hasan Ali Barman

المصدر: Reviews in Cardiovascular Medicine, Vol 25, Iss 2, p 64 (2024)

مصطلحات موضوعية: empagliflozin, type 2 diabetes mellitus, ventricular repolarization, qt interval, arrhythmias, sglt-2 inhibitor, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://www.imrpress.com/journal/RCM/25/2/10.31083/j.rcm2502064Test; https://doaj.org/toc/1530-6550Test

الوصول الحر: https://doaj.org/article/7316a5845d1943f491f3c5cd706fe60cTest

المؤلفون: Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F. Fromm, Roland E. Schmieder, Renke Maas

المصدر: Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-11 (2022)

مصطلحات موضوعية: SGLT-2 inhibitor, Empagliflozin, Dapagliflozin, Type 2 diabetes mellitus, Homoarginine, ADMA, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1475-2840Test

الوصول الحر: https://doaj.org/article/84d0ad9359a24a469e3fdccbc5dcb7eaTest

المؤلفون: Zepeng Shi, Feng Gao, Wei Liu, Xuezhi He

المصدر: Frontiers in Cardiovascular Medicine, Vol 9 (2022)

مصطلحات موضوعية: heart failure, empagliflozin, dapagliflozin, SGLT-2 inhibitor, prognosis, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fcvm.2022.869272/fullTest; https://doaj.org/toc/2297-055XTest

الوصول الحر: https://doaj.org/article/7c78f8cc28e245679865712d9d88814aTest

المؤلفون: Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu

المصدر: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-14 (2019)

مصطلحات موضوعية: Atrial fibrillation, Empagliflozin, SGLT-2 inhibitor, Atrial remodeling, Mitochondrial function, Diabetic rats, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1475-2840Test

الوصول الحر: https://doaj.org/article/c8bcfe7294d740b29b42e41e29df2c01Test

المؤلفون: Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato, Masaaki Okabe

المصدر: Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-9 (2018)

مصطلحات موضوعية: SGLT-2 inhibitor, Epicardial adipose tissue, Diabetes mellitus, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12933-017-0658-8Test; https://doaj.org/toc/1475-2840Test

الوصول الحر: https://doaj.org/article/1188aa5bc4d64318ab8603a9ecf0cd72Test

المؤلفون: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito

المساهمون: Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., Esposito, K.

المصدر: Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)

مصطلحات موضوعية: Male, Kidney Disease, Time Factors, Time Factor, Heart Diseases, Endocrinology, Diabetes and Metabolism, Risk Assessment, Type 2 diabete, Cardiovascular outcome trials, Diseases of the circulatory (Cardiovascular) system, Humans, Sodium-Glucose Transporter 2 Inhibitors, Original Investigation, Aged, Clinical Trials as Topic, Sodium-Glucose Transporter 2 Inhibitor, Cardiorenal outcomes, SGLT-2 inhibitors, Cardiorenal outcome, Type 2 diabetes, Heart Disease Risk Factor, Middle Aged, Cardiovascular outcome trial, Heart Disease, Treatment Outcome, Diabetes Mellitus, Type 2, Heart Disease Risk Factors, RC666-701, SGLT-2 inhibitor, Female, Kidney Diseases, Cardiology and Cardiovascular Medicine, Human

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74ee06316808c9b8baa3d3f2ed4cdb48Test
http://europepmc.org/articles/PMC8680308Test

المؤلفون: Lorenzo Scappaticcio, Dario Giugliano, Miriam Longo, Katherine Esposito, Giuseppe Bellastella

المساهمون: Giugliano, D., Scappaticcio, L., Longo, M., Bellastella, G., Esposito, K.

المصدر: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-5 (2021)
Cardiovascular Diabetology

مصطلحات موضوعية: medicine.medical_specialty, endocrine system, Kidney Disease, GLP-1 receptor agonist, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Incretins, Risk Assessment, Type 2 diabete, Glucagon-Like Peptide-1 Receptor, Risk Factors, Diabetes mellitus, Internal medicine, Cardiovascular Disease, Risk of mortality, medicine, Humans, Diseases of the circulatory (Cardiovascular) system, Sodium-Glucose Transporter 2 Inhibitors, Stroke, Glucagon-like peptide 1 receptor, Protective Factor, Cause of death, GLP-1 receptor agonists, business.industry, Risk Factor, Sodium-Glucose Transporter 2 Inhibitor, SGLT-2 inhibitors, Protective Factors, Incretin, medicine.disease, Hospitalization, Cardiorenal benefits, Cardiorenal benefit, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart failure, RC666-701, SGLT-2 inhibitor, Commentary, Kidney Diseases, Cardiology and Cardiovascular Medicine, business, Mace, Human

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16c3bf36067332f81bbe531ea8ea647Test
http://hdl.handle.net/11591/467157Test